Medicine and Dentistry
Multiple Myeloma
90%
Monoclonal Gammopathy of Undetermined Significance
33%
Nephropathy
33%
Lenalidomide
33%
Overall Survival
23%
Melphalan
16%
Autologous Stem Cell Transplantation
16%
Drug Megadose
16%
Light Chain
14%
Progression Free Survival
13%
Procoagulant
13%
Hypercoagulability
13%
Thromboplastin
10%
Phospholipid
10%
Renal Failure
9%
Neutrophil
6%
Extracellular Trap
6%
DNA
6%
Thrombin
6%
Membrane Microparticle
6%
Keyphrases
Daratumumab
66%
Multiple Myeloma Patients
33%
Tissue Factor Expression
33%
Real-world Outcomes
33%
Carfilzomib
33%
Cast Nephropathy
33%
Line of Therapy
13%
Immunomodulatory Drugs (IMiDs)
13%
Time to Next Treatment
13%
Uninvolved Immunoglobulins
12%
Median Time
11%
Dialysis-dependent Renal Failure
9%
Deep Reduction
9%
Monotherapy
8%
Phenotypical Analysis
6%
Calibrated Automated Thrombogram
6%
Worse Outcome
5%
Clinical High Risk
5%
Overall Response Rate
5%
Treatment Timing
5%
Multiple Myeloma
5%
Standard Risk
5%
Immunology and Microbiology
Multiple Myeloma
100%
Daratumumab
66%
Overall Survival
33%
Tissue Factor
33%
Progression Free Survival
33%
Blood Clotting
11%
Plasma Cell
5%
Thrombin
5%
Drug Megadose
5%
Cyclophosphamide
5%
CD38
5%
Ultracentrifugation
5%
Dexamethasone
5%
Western Blot
5%
Immunoglobulin A
5%
Intravenous Immunoglobulin
5%
Transmission Electron Microscopy
5%
